Azenta announced that it has completed the sale of its B Medical Systems business to Thelema S.à r.l., marking the close of a transaction that was first announced in late December 2025. The deal officially closed on July 1, 2026 after all required closing conditions were satisfied, supporting Azenta’s strategy of sharpening its focus on its core life sciences operations.
Under the terms of the agreement, Azenta sold B Medical Systems for a fixed purchase price of $63 million in cash. As part of the transaction structure, $35 million of the purchase price was financed through a short-term secured vendor loan provided by an Azenta subsidiary to Thelema. The company said additional details regarding the transaction are available in its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission.
By divesting B Medical Systems, Azenta intends to simplify its business portfolio while concentrating resources on its primary life sciences growth platforms. The company believes the transaction will improve financial flexibility and allow it to continue investing in areas such as sample management solutions and multiomics services for pharmaceutical, biotechnology, academic, and healthcare customers worldwide.
Azenta provides cold-chain sample management technologies and multiomics services that support drug development, clinical research, and advanced cell therapies. Its portfolio includes brands such as GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey.
KEY QUOTE:
“The completion of this transaction advances our strategy to simplify and focus the portfolio on our core life sciences businesses. With enhanced financial flexibility and a continued focus on our core growth platforms, we are well positioned to drive sustainable growth and long-term value for our shareholders.”
John Marotta, President and Chief Executive Officer of Azenta
